Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
Sponsor: Eisai Co., Ltd.
Summary
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA in routine clinical practice in participants treated with lecanemab.
Official title: A Multicenter, Postmarketing Observational Study to Evaluate Safety Regarding Amyloid-Related Imaging Abnormalities and Their Management in Patients With Early Alzheimer's Disease and Treated With Lecanemab
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
5000
Start Date
2024-02-14
Completion Date
2027-12-31
Last Updated
2026-01-23
Healthy Volunteers
No
Conditions
Interventions
No Intervention
This is a non-interventional study.
Locations (3)
Eisai trial site 2
Hiroshima, Japan
Eisai trial site 3
Kyoto, Japan
Eisai trial site 1
Tokyo, Japan